Functional outcome and prognostic factors in anti-Jo1 patients with antisynthetase syndrome

Arthritis Research and Therapy

Volumn 15, Issue 5, 2013, Pages

  Marie, Isabelle ^a,b   Hatron, Pierre Yves ^c   Cherin, Patrick ^d   Hachulla, Eric ^c   Diot, Elisabeth ^e   Vittecoq, Olivier ^a   Menard, Jean François ^a   Jouen, Fabienne ^b   Dominique, Stéphane ^a  

^a ROUEN UNIVERSITY HOSPITAL   (France)

^b UNIVERSITÉ DE ROUEN   (France)

^c LILLE UNIVERSITY HOSPITAL   (France)

^d PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^e UNIVERSITY HOSPITAL OF TOURS   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CYCLOPHOSPHAMIDE; IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT; JO 1 ANTIBODY; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; RITUXIMAB; STEROID; ANTINUCLEAR ANTIBODY; HISTIDINE TRANSFER RNA LIGASE; JO-1 ANTIBODY;

ADOLESCENT; ADULT; AGED; ANTISYNTHETASE SYNDROME; ARTICLE; ASPIRATION PNEUMONIA; DISEASE SEVERITY; DRUG MEGADOSE; FEMALE; FOLLOW UP; FRAGILITY FRACTURE; GENERAL CONDITION DETERIORATION; HEALTH ASSESSMENT QUESTIONNAIRE; HUMAN; INTERSTITIAL LUNG DISEASE; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MONOTHERAPY; MORTALITY; MUSCLE WEAKNESS; MYOSITIS; NEOPLASM; PAIN; PERCUTANEOUS ENDOSCOPIC GASTROSTOMY; QUALITY OF LIFE; REMISSION; RESPIRATORY FAILURE; RETROSPECTIVE STUDY; SKIN CALCIFICATION; SKIN ULCER; SPINE FRACTURE; STEROID THERAPY; STOMACH INTUBATION; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT; IMMUNOLOGY; MIDDLE AGED; OUTCOME ASSESSMENT; PATHOLOGY; PROGNOSIS; QUESTIONNAIRE; RECURRENT DISEASE; SEVERITY OF ILLNESS INDEX; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, ANTINUCLEAR; AZATHIOPRINE; FEMALE; FOLLOW-UP STUDIES; HISTIDINE-TRNA LIGASE; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOSUPPRESSIVE AGENTS; MALE; METHOTREXATE; MIDDLE AGED; MYOSITIS; OUTCOME ASSESSMENT (HEALTH CARE); PROGNOSIS; QUESTIONNAIRES; RECURRENCE; REMISSION INDUCTION; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; STEROIDS; YOUNG ADULT;

EID: 84885011165     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/ar4332     Document Type: Article

References (36)

1. Marguerie C, Bunn CC, Beynon HL, Bernstein RM, Hughes JM, So AK, Walport MJ. Polymyositis, pulmonary fibrosis and autoantibodies to aminoacyl-tRNA synthetase enzymes. Q J Med 1990, 77:1019-1038. 10.1093/qjmed/77.1.1019, 2267280.
2. Marie I, Dominique S, Janvresse A, Levesque H, Menard JF. Rituximab therapy for refractory interstitial lung disease related to antisynthetase syndrome. Respir Med 2012, 106:581-587. 10.1016/j.rmed.2012.01.001, 22280877.
3. Marie I, Josse S, Hatron PY, Dominique S, Hachulla E, Janvresse A, Cherin P, Mouthon L, Vittecoq O, Menard JF, Jouen F. Interstitial lung disease in anti-Jo-1 patients with antisynthetase syndrome. Arthritis Care Res (Hoboken) 2013, 65:800-808. 10.1002/acr.21895, 23203765.
4. Marie I. Morbidity and mortality in adult polymyositis and dermatomyositis. Curr Rheumatol Rep 2012, 14:275-285. 10.1007/s11926-012-0249-3, 22410829.
5. Katzap E, Barilla-LaBarca ML, Marder G. Antisynthetase syndrome. Curr Rheumatol Rep 2011, 13:175-181. 10.1007/s11926-011-0176-8, 21455765.
6. Love LA, Leff RL, Fraser DD, Targoff IN, Dalakas M, Plotz PH, Miller FW. A new approach to the classification of idiopathic inflammatory myopathy: myositis-specific autoantibodies define useful homogeneous patient groups. Medicine (Baltimore) 1991, 70:360-374.
7. Späth M, Schröder M, Schlotter-Weigel B, Walter MC, Hautmann H, Leinsinger G, Pongratz D, Müller-Felber W. The long-term outcome of anti-Jo-1-positive inflammatory myopathies. J Neurol 2004, 251:859-864.
8. Bohan A, Peter JB. Polymyositis and dermatomyositis (first of two parts). N Engl J Med 1975, 292:344-347. 10.1056/NEJM197502132920706, 1090839.
9. Bohan A, Peter JB. Polymyositis and dermatomyositis (second of two parts). N Engl J Med 1975, 292:403-407. 10.1056/NEJM197502202920807, 1089199.
10. Marie I, Hachulla E, Hatron PY, Hellot MF, Levesque H, Devulder B, Courtois H. Polymyositis and dermatomyositis: short term and longterm outcome, and predictive factors of prognosis. J Rheumatol 2001, 28:2230-2237.
11. Quanjer PH. Clinical respiratory physiology: standardized lung function testing: working party report: standardization of lung function tests. Bull Eur Physiopathol Respir 1983, 19(Suppl 5):1-95.
12. Marie I, Hatron PY, Dominique S, Cherin P, Mouthon L, Menard JF. Short-term and long-term outcomes of interstitial lung disease in polymyositis and dermatomyositis: a series of 107 patients. Arthritis Rheum 2011, 63:3439-3447. 10.1002/art.30513, 21702020.
13. Clarke AE, Bloch DA, Medsger TA, Oddis CV. A longitudinal study of functional disability in a national cohort of patients with polymyositis/dermatomyositis. Arthritis Rheum 1995, 38:1218-1224. 10.1002/art.1780380907, 7575715.
14. Kalmijn S, van Venrooij WJ, Voskuyl AE, Dinant HJ, Linssen WH, Wokke JH, Hoogendijk JE. Long-term outcome in polymyositis and dermatomyositis. Ann Rheum Dis 2006, 65:1456-1461. 10.1136/ard.2005.045690, 1798355, 16606652.
15. Dankó K, Ponyi A, Constantin T, Borgulya G, Szegedi G. Long-term survival of patients with idiopathic inflammatory myopathies according to clinical features: a longitudinal study of 162 cases. Medicine (Baltimore) 2004, 83:35-42. 10.1097/01.md.0000109755.65914.5e, 14747766.
16. Henriksson KG, Sandstedt P. Polymyositis-treatment and prognosis: a study of 107 patients. Acta Neurol Scand 1982, 65:280-300. 10.1111/j.1600-0404.1982.tb03087.x, 7102257.
17. Hochberg MC, Lopez-Acuna D, Gittelsohn A. Mortality from polymyositis and dermatomyositis in the United States, 1968-1978. Arthritis Rheum 1983, 26:1465-1471. 10.1002/art.1780261208, 6651895.
18. Koh ET, Seow A, Ong B, Ratnagopal P, Tjia H, Chng HH. Adult onset polymyositis/dermatomyositis: clinical and laboratory features and treatment response in 75 patients. Ann Rheum Dis 1993, 52:857-861. 10.1136/ard.52.12.857, 1005215, 8311535.
19. Sultan SM, Ioannou Y, Moss K, Isenberg DA. Outcome in patients with idiopathic inflammatory myositis: morbidity and mortality. Rheumatology (Oxford) 2002, 41:22-26.
20. Uthman I, Vázquez-Abad D, Senécal JL. Distinctive features of idiopathic inflammatory myopathies in French Canadians. Semin Arthritis Rheum 1996, 26:447-458. 10.1016/S0049-0172(96)80025-4, 8870112.
21. Yamasaki Y, Yamada H, Ohkubo M, Yamasaki M, Azuma K, Ogawa H, Mizushima M, Ozaki S. Longterm survival and associated risk factors in patients with adult-onset idiopathic inflammatory myopathies and amyopathic dermatomyositis: experience in a single institute in Japan. J Rheumatol 2011, 38:1636-1643. 10.3899/jrheum.101002, 21572147.
22. Joffe MM, Love LA, Leff RL, Fraser DD, Targoff IN, Hicks JE, Plotz PH, Miller FW. Drug therapy of the idiopathic inflammatory myopathies: predictors of response to prednisone, azathioprine, and methotrexate and a comparison of their efficacy. Am J Med 1993, 94:379-387. 10.1016/0002-9343(93)90148-I, 8386437.
23. Marie I, Mouthon L. Therapy of polymyositis and dermatomyositis. Autoimmun Rev 2011, 11:6-13. 10.1016/j.autrev.2011.06.007, 21740984.
24. Ponyi A, Borgulya G, Constantin T, Váncsa A, Gergely L, Dankó K. Functional outcome and quality of life in adult patients with idiopathic inflammatory myositis. Rheumatology (Oxford) 2005, 44:83-88. 10.1093/rheumatology/keh404, 15381789.
25. Aggarwal R, Cassidy E, Fertig N, Koontz DC, Lucas M, Ascherman DP, Oddis CV. Patients with non-Jo-1 anti-tRNA-synthetase autoantibodies have worse survival than Jo-1 positive patients. Ann Rheum Dis in press. doi:10.1136/annrheumdis-2012-201800.
26. Schiopu E, Phillips K, MacDonald PM, Crofford LJ, Somers EC. Predictors of survival in a cohort of patients with polymyositis and dermatomyositis: effect of corticosteroids, methotrexate, and azathioprine. Arthritis Res Ther 2012, 14:R22. 10.1186/ar3704, 3392815, 22284862.
27. Marie I, Menard JF, Hatron PY, Hachulla E, Mouthon L, Tiev K, Ducrotte P, Cherin P. Intravenous immunoglobulins for steroid-refractory esophageal involvement related to polymyositis and dermatomyositis: a series of 73 patients. Arthritis Care Res (Hoboken) 2010, 62:1748-1755. 10.1002/acr.20325, 20722047.
28. Oddis CV, Reed AM, Aggarwal R, Rider LG, Ascherman DP, Levesque MC, Barohn RJ, Feldman BM, Harris-Love MO, Koontz DC, Fertig N, Kelley SS, Pryber SL, Miller FW, Rockette HE, RIM Study Group Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis: a randomized, placebo-phase trial. Arthritis Rheum 2013, 65:314-324. RIM Study Group.
29. Marie I, Hatron PY, Levesque H, Hachulla E, Hellot MF, Michon-Pasturel U, Courtois H, Devulder B. Influence of age on characteristics of polymyositis and dermatomyositis in adults. Medicine (Baltimore) 1999, 78:139-147. 10.1097/00005792-199905000-00001, 10352646.
30. Marie I, Hatron PY, Hachulla E, Wallaert B, Michon-Pasturel U, Devulder B. Pulmonary involvement in polymyositis and in dermatomyositis. J Rheumatol 1998, 25:1336-1343.
31. Buchbinder R, Forbes A, Hall S, Dennett X, Giles G. Incidence of malignant disease in biopsy-proven inflammatory myopathy: a population-based cohort study. Ann Intern Med 2001, 134:1087-1095. 10.7326/0003-4819-134-12-200106190-00008, 11412048.
32. Legault D, McDermott J, Crous-Tsanaclis AM, Boire G. Cancer-associated myositis in the presence of anti-Jo1 autoantibodies and the antisynthetase syndrome. J Rheumatol 2008, 35:169-171.
33. Rozelle A, Trieu S, Chung L. Malignancy in the setting of the anti-synthetase syndrome. J Clin Rheumatol 2008, 14:285-288. 10.1097/RHU.0b013e31817d116f, 18664993.
34. Yu KH, Wu YJ, Kuo CF, See LC, Shen YM, Chang HC, Luo SF, Ho HH, Chen IJ. Survival analysis of patients with dermatomyositis and polymyositis: analysis of 192 Chinese cases. Clin Rheumatol 2011, 30:1595-1601. 10.1007/s10067-011-1840-0, 21915609.
35. Torres C, Belmonte R, Carmona L, Gómez-Reino FJ, Galindo M, Ramos B, Cabello A, Carreira PE. Survival, mortality and causes of death in inflammatory myopathies. Autoimmunity 2006, 39:205-215. 10.1080/08916930600622603, 16769654.
36. Marie I, Lahaxe L, Benveniste O, Delavigne K, Adoue D, Mouthon L, Hachulla E, Constans J, Tiev K, Diot E, Levesque H, Boyer O, Jouen F. Long-term outcome of patients with polymyositis/dermatomyositis and anti-PM-Scl antibody. Br J Dermatol 2010, 162:337-344. 10.1111/j.1365-2133.2009.09484.x, 19845665.